Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma

• Published in: Experimental and therapeutic medicine Vol. 12; no. 6; pp. 3813 - 3819
• Main Authors: Zhao, Yin-Nong, Zhang, Yong-Quan, Ye, Jia-Zhou, Liu, Xing, Yang, Hong-Zhi, Cong, Feng-Yun, Xiang, Bang-De, Wu, Fei-Xiang, Ma, Liang, Li, Le-Qun, Ye, Hai-Hong
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.12.2016; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Blood clots; Blood platelets; Care and treatment; Chemoembolization; Comparative analysis; Confidence intervals; Diagnosis; Excision (Surgery); hepatic resection; Hepatitis; hepatocellular carcinoma; Hepatoma; Hospitals; Hypertension; Liver cancer; Mortality; overall survival rate; recurrence-free survival; Surgery; Therapeutic chemoembolization; transarterial chemoembolization; Tumors; Ultrasonic imaging; overall survival rate; hepatic resection; transarterial chemoembolization; recurrence-free survival; hepatocellular carcinoma
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2016.3810

The present study aimed to compare the overall and recurrence-free survival rates following hepatic resection (HR) and transcatheter arterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) classified intermediate-stage Child-Pugh A hepatocellular carcinoma (HCC). A total of 443 patients were examined, among whom 274 underwent HR, whereas 169 received TACE. The overall survival, recurrence-free survival between groups and subgroups, and risk factors with respect to mortality and recurrence, were analyzed. The 1-, 3- and 5-year overall and recurrence-free survival rates were 70, 46 and 37% and 73, 52, and 37%, respectively after HR, compared with 38, 15, and 12% and 44, 25 and 16%, respectively after TACE. Overall and recurrence-free survival rates were significantly increased following HR compared with TACE. Subgroup analysis in the multi-nodule group showed that the 1-, 3- and 5-year overall survival rates were 68, 38 and 30% after HR, compared with 36, 10 and 0% following TACE. In the solitary tumor group, 1-, 3- and 5-year overall survival rates were 71, 50 and 38% after HR, and 41, 22 and 15% after TACE. The overall survival rate after HR was significantly increased compared with that after TACE in the solitary tumor and multi-nodule groups. The risk factors for mortality include solitary tumor diameter >10 cm, multi-nodules, serum albumin level ≥35 g/l, prothrombin time >13 sec, alphafetoprotein levels >400 ng/ml, and patients with hepatitis B virus. Solitary tumor diameter >10 cm, multi-nodules, and hepatitis B virus (P<0.001) were found to be associated with higher recurrence of HCC. Overall and recurrence-free survival rates were improved after HR compared with those after TACE in BCLC stage B, Child-Pugh A, HCC patients.